Mitochondrial Myopathies: Clinical Trials

25 trials for Mitochondrial Myopathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 4 terminated, 3 unknown, 2 recruiting. 25 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 225Completed 13, Terminated 4, Unknown 3, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Suspended 1
Phase 13Completed 2, Not yet recruiting 1
Phase 31Terminated 1

Follow Mitochondrial Myopathies: new trials by email Literature Review of Mitochondrial Myopathies trials Research Report on Mitochondrial Myopathies

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Phase 1 / Phase 2Not yet recruitingGeorge Washington University242027-03-012026-10-05
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
zagociguat 15mg - Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Phase 2TerminatedTisento Therapeutics372025-08-182026-11-06
A Study to Assess TTI-0102 vs Placebo in MELAS Patients
TTI-0102, Placebo - MELAS Syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
Phase 2CompletedThiogenesis Therapeutics, Inc.92025-05-122026-07-24
Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency
Doxecitine and Doxribtimine - Thymidine Kinase 2 (TK2 ) Deficiency, Mitochondrial Myopathies
Phase 2RecruitingCristina Domínguez González152025-01-012026-09-17
A Phase 2b Study of Zagociguat in Patients With MELAS
zagociguat 15mg, zagociguat 30mg, Placebo - Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Phase 2CompletedTisento Therapeutics432024-09-102026-10-23
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies
Phase 1 / Phase 2CompletedChildren's Hospital of Philadelphia162023-09-222024-11-29
Effect and Safety MABs Administration m.3243A>G Mutation Carriers
Intra-arterial delivery of autologous MABs - Mitochondrial Myopathies
Phase 2UnknownMaastricht University202023-08-012024-04-15
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy
Nicotinamide Riboside, Placebo - Mitochondrial Myopathy
Phase 2Active not recruitingRalitza Gavrilova342023-05-262026-01-26
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)
OMT-28 - Primary Mitochondrial Disease
Phase 2CompletedOmeicos Therapeutics GmbH282023-05-222026-01-22
Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome
deoxycytidine and deoxythymidine - Mitochondrial Diseases, Mitochondrial Encephalomyopathy
Phase 2RecruitingKenneth Myers, MD2002021-10-182026-10-19
The KHENEREXT Study
Oral administration of 100 mg KH176 twice daily - Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
Phase 2CompletedKhondrion BV112021-08-092024-03-06
The KHENERGYC Study
Sonlicromanol, Placebo - Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
Phase 2SuspendedKhondrion BV242021-02-012025-01-10
Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
IW-6463 Tablets - MELAS
Phase 2TerminatedTisento Therapeutics82020-11-132024-08-29
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy
Phase 2 / Phase 3TerminatedPTC Therapeutics682020-09-282026-03-31
The KHENERGYZE Study
KH176, Placebo - Mitochondrial Diseases, Mitochondrial Myopathies
Phase 2CompletedKhondrion BV272019-10-302022-08-31
The KHENERGY Study
KH176, placebo - Mitochondrial Diseases, Mitochondrial Myopathies
Phase 2CompletedKhondrion BV202016-09-012018-02-23
Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study
Elamipretide, Placebo - Primary Mitochondrial Disease
Phase 2CompletedStealth BioTherapeutics Inc.302016-08-222020-07-17
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
Cysteamine Bitartrate - Mitochondrial Diseases
Phase 2TerminatedAmgen222015-05-192024-12-27
RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR
Omaveloxolone capsules, 2.5 mg, omaveloxolone capsules, 5 mg, omaveloxolone capsules, 10 mg - MItochondrial Myopathies
Phase 2CompletedBiogen532015-05-052025-06-05
Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
elamipretide (low dose), elamipretide (intermediate dose), elamipretide (high dose) - Mitochondrial Myopathy
Phase 1 / Phase 2CompletedStealth BioTherapeutics Inc.362015-02-012019-12-27

Showing 20 of 25. Sign in to see all of them.

Narrower conditions

MELAS Syndrome (15)  ·  Mitochondrial Diseases (11)  ·  Acidosis, Lactic (6)  ·  Mitochondrial Encephalomyopathies (6)  ·  Mitochondrial encephalopathy (5)  ·  Leigh Disease (4)  ·  MERRF Syndrome (3)  ·  Ophthalmoplegia, Chronic Progressive External (3)  ·  Seizures (3)  ·  Epilepsies, Myoclonic (2)  ·  Muscular Diseases (2)  ·  Noninsulin-dependent diabetes mellitus with deafness (2)  ·  Optic Atrophy, Hereditary, Leber (2)  ·  Anxiety Disorders (1)

Broader conditions

Metabolic Diseases (25)  ·  Musculoskeletal Diseases (25)  ·  Nervous System Diseases (25)  ·  Neuromuscular Diseases (25)  ·  Nutritional and Metabolic Diseases (25)  ·  Muscular Diseases (23)  ·  Brain Diseases (18)  ·  Brain Diseases, Metabolic (18)  ·  Central Nervous System Diseases (18)  ·  Brain Diseases, Metabolic, Inborn (17)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (17)  ·  Genetic Diseases, Inborn (17)  ·  Metabolism, Inborn Errors (17)  ·  Cardiovascular Diseases (15)  ·  Cerebral Small Vessel Diseases (15)

Interventions

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (3)  ·  Cysteamine (2)  ·  arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide (2)  ·  Arginine (1)  ·  Bulk Drugs (1)  ·  Deoxycytidine (1)  ·  Dichloroacetic Acid (1)  ·  Exercise (1)  ·  ORF 50 transactivator (1)  ·  Thymidine (1)  ·  alpha-tocotrienol quinone (1)  ·  cysteamine-pantetheine disulfide (1)  ·  idebenone (1)  ·  nicotinamide-beta-riboside (1)  ·  omaveloxolone (1)

Sponsors

Khondrion BV (4)  ·  Tisento Therapeutics (3)  ·  Amgen (2)  ·  Stealth BioTherapeutics Inc. (2)  ·  Biogen (1)  ·  Children's Hospital of Philadelphia (1)  ·  Cristina Domínguez González (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  George Washington University (1)  ·  Kenneth Myers, MD (1)  ·  Maastricht University (1)  ·  Michio Hirano (1)  ·  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)  ·  Omeicos Therapeutics GmbH (1)  ·  PTC Therapeutics (1)

Countries

United States (15)  ·  Netherlands (7)  ·  Germany (5)  ·  United Kingdom (5)  ·  Canada (4)  ·  Italy (4)  ·  Denmark (3)  ·  Australia (2)  ·  France (2)  ·  Spain (2)  ·  Japan (1)  ·  Poland (1)  ·  Sweden (1)

Top investigators

Anne Chiaramello, Ph.D. (1)  ·  Chad Glasser, PharmD (1)  ·  Darryl C De Vivo, MD (1)  ·  Debra Regier, M.D., Ph.D. (1)  ·  Elizabeth M McCormick, MS (1)  ·  Ingrid Tein, MD (1)  ·  Janneke Hoeijmakers, MD, PhD (1)  ·  Jim Carr (1)  ·  Kenneth Alexis MD Myers, MD PhD FRCPC (1)  ·  Lonneke de Boer, MD (1)  ·  Michio Hirano, MD (1)  ·  Patrice P Rioux, MD, PhD (1)  ·  Ralitza H. Gavrilova, MD (1)

Results publications

PMID 11182283, PMID 12013896, PMID 12508073, PMID 12771225, PMID 12826641, PMID 15090651, PMID 15684706, PMID 16621917, PMID 16971696, PMID 16971699, PMID 17080429, PMID 17353390, PMID 17483096, PMID 17486094, PMID 17549623, PMID 18238797, PMID 18467430, PMID 18546365, PMID 19103785, PMID 19125351, PMID 19138848, PMID 19192035, PMID 19667227, PMID 19766516, PMID 19889013, PMID 20301762, PMID 20301791, PMID 20329599, PMID 20444604, PMID 21483760, PMID 21774628, PMID 21855607, PMID 22084276, PMID 22176657, PMID 22608879, PMID 22711161, PMID 23168274, PMID 23169334, PMID 23230576, PMID 23385875, PMID 23714749, PMID 23817075, PMID 245993, PMID 24708634, PMID 24985751, PMID 25857492, PMID 25993630, PMID 26342080, PMID 26760297, PMID 27554452

NIH funding

R01AR050597 (1), U54NS078059 (1), UH3TR003897 (1)